RP

Rajeev Poikayil Ramarajan

Active Director Director DIN 09677552
DIN 09677552 First appointment Jul 2022 Primary industry Life Sciences
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Jul 2022
Shareholding value β€’β€’β€’β€’ Premium profile

About Rajeev Poikayil Ramarajan

Data last updated:

Rajeev Poikayil Ramarajan is a Director at Enzygen Biolabs Private Limited (since 2022). The company operates in Life Sciences.

DIN 09677552
Primary Designation Director
Industry Life Sciences
First Appointment 19 Jul 2022
Oldest Company Age 4 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Enzygen Biolabs Private Limited U73100KL2022PTC076855
Director19 Jul 20222022Active

Board colleagues of Rajeev Poikayil Ramarajan

NameDINCompanyDesignation
Aparna Chandrasekhar09677563Enzygen Biolabs Private LimitedDirector

Directorship timeline

Open interactive timeline →
Enzygen Biolabs Private Limited
Premium access

Shareholding and investment profile for Rajeev Poikayil Ramarajan

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Rajeev Poikayil Ramarajan

Rajeev Poikayil Ramarajan currently holds 1 directorship: Enzygen Biolabs Private Limited (Director, since 19 Jul 2022).

Rajeev Poikayil Ramarajan was first appointed on 19 Jul 2022 as Director at Enzygen Biolabs Private Limited.

The current boards of Rajeev Poikayil Ramarajan's companies include Aparna Chandrasekhar (Enzygen Biolabs Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available